A 2-week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Tolerability and Pharmacokinetics of Orally Administered AZD9668 in Patients With COPD.
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2012
At a glance
- Drugs Alvelestat (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Pharmacokinetics
- 31 Aug 2018 Biomarkers information updated
- 28 Dec 2010 Actual end date changed from 1 Oct 2008 to 1 Sep 2008 as reported by ClinicalTrials.gov.
- 03 Nov 2008 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.